Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Stock Price Down 15.4% - Here's Why

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) traded down 15.4% during trading on Friday . The stock traded as low as $27.06 and last traded at $27.06. 785 shares were traded during trading, an increase of 283% from the average session volume of 205 shares. The stock had previously closed at $31.99.

Swedish Orphan Biovitrum Stock Down 15.4%

The company's 50-day moving average price is $29.99 and its 200 day moving average price is $29.23. The stock has a market cap of $9.63 billion, a PE ratio of 25.53 and a beta of 0.44. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.71 and a current ratio of 1.04.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.04. The company had revenue of $641.33 million during the quarter, compared to analyst estimates of $644.12 million. Swedish Orphan Biovitrum had a net margin of 15.07% and a return on equity of 10.54%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.